Federal Cannabis Banking Restrictions (United States)

Why cannabis banking is a problem

Cannabis remains a Schedule I substance under the federal Controlled Substances Act ^[1]. That status means revenue from cannabis sales — even sales that are fully legal under state law — is considered proceeds of federal drug trafficking. Under federal money laundering statutes (18 U.S.C. §§1956–1957), a bank that knowingly handles such proceeds can face criminal liability, civil penalties, and the loss of its federal deposit insurance or charter ^[2].

This is the core of the 'cannabis banking problem.' It is not that banking cannabis is explicitly prohibited by a single statute; it is that the existing framework of federal drug law, the Bank Secrecy Act, and anti–money laundering rules creates significant legal exposure for any federally regulated financial institution that serves the industry.

The 2014 FinCEN guidance

In February 2014, the Treasury Department's Financial Crimes Enforcement Network (FinCEN) issued guidance (FIN-2014-G001) describing how banks could serve marijuana-related businesses while meeting Bank Secrecy Act obligations ^[3]. The guidance did not legalize cannabis banking; it explained the reporting expectations if a bank chose to take on the risk.

Under the guidance, banks must:

• Conduct enhanced due diligence on cannabis clients.
• File a 'Marijuana Limited' Suspicious Activity Report (SAR) for routine state-legal activity, a 'Marijuana Priority' SAR if red flags suggest federal enforcement priorities are implicated, or a 'Marijuana Termination' SAR when ending the relationship.
• Monitor ongoing compliance with the now-rescinded Cole Memo enforcement priorities (anti-diversion to minors, no cartel involvement, etc.).

As of early 2024, FinCEN reported several thousand depository institutions filing marijuana-related SARs, though the number actively banking the industry is smaller — many file SARs only because a client unexpectedly turned out to be cannabis-adjacent ^[4].

Practical consequences for cannabis businesses

The banking restriction cascades into several day-to-day realities for state-licensed operators:

Cash-heavy operations. Many dispensaries cannot get checking accounts at major national banks. Some work with state-chartered credit unions or community banks that have built compliance programs; others operate largely in cash, which creates safety and accounting risks ^[5].

No standard card payments. Visa, Mastercard, American Express, and Discover prohibit cannabis transactions on their networks. Workarounds like 'cashless ATM' systems have been targeted by card networks for misrepresenting transactions, and several were shut down in 2021–2023 ^[6].

Limited access to loans and capital. SBA loans are unavailable to plant-touching cannabis businesses, and most large lenders will not extend mortgages or equipment financing to them. Capital tends to come from private equity, specialized REITs, or high-interest private lenders.

IRS §280E. Separate from banking, federal tax code §280E forbids businesses 'trafficking' in Schedule I or II substances from deducting ordinary business expenses (rent, payroll, marketing). Cannabis retailers commonly pay effective federal tax rates well above 50% of net income ^[7]. §280E is a tax issue, not a banking issue, but it compounds the financial strain.

Legislative efforts: SAFE / SAFER Banking

The Secure and Fair Enforcement (SAFE) Banking Act, first introduced in 2019, would prohibit federal regulators from penalizing banks solely for serving state-legal cannabis businesses. It has passed the U.S. House of Representatives seven times in various forms but has never been enacted into law ^[8].

A revised version, the SAFER Banking Act (S.2860), was reported out of the Senate Banking Committee in September 2023 with bipartisan support. As of the last-verified date on this article (June 2024), it has not received a floor vote in the full Senate and is not law ^[9].

If passed, SAFER would not legalize cannabis or change its Schedule I status. It would create a safe harbor for depository institutions and ancillary service providers (payment processors, insurers, accountants) — addressing the banking symptom without resolving the underlying federal prohibition.

Rescheduling and what it would (and wouldn't) change

In May 2024, the U.S. Department of Justice formally proposed moving cannabis from Schedule I to Schedule III of the Controlled Substances Act, following a recommendation by the Department of Health and Human Services ^[10]. The proposal entered a public comment and administrative review period and is not final as of the last-verified date.

Rescheduling to Schedule III, if finalized, would:

• End the application of IRC §280E to cannabis businesses (a major financial change).
• Not, by itself, make state-legal recreational sales federally legal. Schedule III substances still require FDA approval and a prescription for lawful distribution.
• Not automatically resolve the banking problem, because state-legal adult-use sales would still technically violate federal law, just under a less severe schedule.

In other words, rescheduling helps with taxes more than with banking. Full banking normalization still depends on either federal legalization or a SAFER-style safe harbor.

Not legal advice

This article is informational only and is not legal, tax, or financial advice. Federal cannabis policy is changing; state laws vary widely; and any specific situation — opening an account, structuring a business, accepting payments, filing taxes — should be reviewed with a qualified attorney, CPA, or compliance officer licensed in the relevant jurisdiction.

Last verified: June 2024. Check the status of the SAFER Banking Act, the DEA rescheduling rulemaking, and FinCEN guidance for any updates after that date.

Sources

How this page was made